Dr Smith speaks with ecancertv at the 2016 San Antonio Breast Cancer Symposium about results from the IBIS-1 trial of tamoxifen as a chemopreventive treatment for women at higher risk of developing breast cancer.

He notes a significant rate of discontinuation of therapy from women experiencing natural symptoms of menopause, which might be mistaken for side effects of the tamoxifen.

Dr Smith considers room for improvement communication to clarify potential outcomes and risks for trial patients.